REG - Verici Dx PLC - Launch of PTRA Assay using Verici Dx's technology

Verici DxAnnouncement

31/07/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240731:nRSe4798Ya&default-theme=true

RNS Number : 4798Y  Verici Dx PLC  31 July 2024

Verici Dx plc

("Verici Dx" or the "Company")

 

Successful completion of Thermo Fisher Scientific licensing and
commercialisation agreement

Formal launch of Pre-Transplant Risk Assessment Assay using Verici's
prognostic testing technology

 

Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for
organ transplant, notes that Thermo Fisher Scientific, the world leader in
serving science, has announced the formal launch of its One Lambda™
Pre-Transplant Risk Assessment ("PTRA") Assay via its CLIA facility in
Fishers, Indiana, utilizing the pre-transplant prognostic testing technology
licensed by the Company to Thermo Fisher Scientific under the terms of a
global licensing and commercialisation agreement announced on 15 November 2023
(the "Agreement").(1)

 

Commenting on the milestones, Sara Barrington, CEO of Verici Dx, said:

 

"I am delighted to see that the PTRA Assay is being launched to the clinical
community so swiftly and look forward to seeing how it can help transform
patient outcomes. Together with the successful transfer of technology, this
demonstrates our Company's commitment to timely and effective collaboration
when executing these types of agreements."

 

Tina Liedtky, President, Transplant Diagnostics, Thermo Fisher Scientific
said:

 

"We're excited to introduce this innovative new tool that may help clinicians
make more informed decisions about post-transplant management by providing
information about patient risk of early acute rejection based on a patient's
unique gene profile prior to transplant."

 

 

Enquiries:

 

 Verici Dx                                                www.v (http://www.vericidx.com) ericidx (http://www.vericidx.com) .com
                                                          (http://www.vericidx.com)
 Sara Barrington, CEO                                     investors@vericidx.com
 Julian Baines, Chairman

 Singer Capital Markets (Nominated Adviser & Broker)      Tel: +44 20 7496 3000
 Phil Davies / Sam Butcher

 

 

Notes

1.     Please refer to RNS number 4652T for further information. A copy of
this announcement can also be found on the company website
https://verici-dx-plc.flint-platform.com/regulatory-news/62760
(https://verici-dx-plc.flint-platform.com/regulatory-news/62760)

 

 

About Verici Dx plc www.vericidx.com (http://www.vericidx.com)

Verici Dx is a developer of a complementary suite of leading-edge tests
forming a kidney transplant platform for personalised patient and organ
response risk to assist clinicians in medical management for improved patient
outcomes. The underlying technology is based upon artificial intelligence
assisted transcriptomic analysis to provide RNA signatures focused upon the
immune response and other biological pathway signals critical for transplant
prognosis of risk of injury, rejection and graft failure from pre-transplant
to late stage. The Company also has a mission to accelerate the pace of
innovation by research using the fully characterised data from the underlying
technology, including through collaboration with medical device,
biopharmaceutical and data science partners.

 

The foundational research was driven by a deep understanding of cell-mediated
immunity and is enabled by access to expertly curated collaborative studies in
highly informative cohorts in kidney transplant.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCQKKBPKBKBCON